// App-Quantinova.ai

PB1624 : MAGROLIMAB + AZACITIDINE VERSUS AZACITIDINE + PLACEBO IN UNTREATED, HIGHER-RISK (HR) MYELODYSPLASTIC SYNDROME: THE PHASE 3, RANDOMIZED, ENHANCE STUDY

Researchers

Presenter

  • Guillermo Garcia-Manero

Principal Investigators

  • Naval G. Daver

  • Jin Xu

  • Mark Chao

  • Trisha Chung

  • Vivian Wang

  • Andrew H. Wei

  • Paresh Vyas

  • David A. Sallman

Medical Centers

  • Gilead Sciences, Inc., Foster City, CA, United States.

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Moffitt Cancer Center, Tampa, Florida, United States

  • The Alfred Hospital and Monash University, Melbourne, Australia

  • University of Oxford, Oxford, United Kingdom

Locations

  • United States

  • Australia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute myelocytic leukemia

  • Anemia

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Vidaza

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cross Over

  • Dose Escalation

Phase

  • III

Study Id's

  • NCT04313881

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved